News

Developed with the Alliance for Longevity Initiatives / Healthspan Action Coalition. Fleming presented it at the Reagan-Udall Foundation in May 2026.

But Justice says the organization is engaging with the broader debate over how gerotherapeutics might eventually navigate regulatory pathways – including through recent discussions at the Reagan-Udall Foundation.

Hosted by the Reagan-Udall Foundation for the FDA, the meeting brings together representatives from federal agencies, clinicians, researchers, and patient organizations to discuss approaches for identifying promising drug repurposing candidates for…

Hybrid public meeting on August 5th will explore approaches to selecting and prioritizing promising FDA-approved drugs for repurposing, with the potential to accelerate patient access to effective therapies for significant unmet medical needs.

On July 21, the Reagan-Udall Foundation for the Food and Drug Administration held its 2026 Annual Public Meeting of the Board of Directors.

The FDA biomedical innovation hearing featured five witnesses: Susan Winckler from the Reagan-Udall Foundation for the FDA, Aaron J. Kowalski from Breakthrough T1D, Dr. Thomas Hwang from Brigham and Women's Hospital and Harvard Medical School, Dr.…

On July 15, 2026, the House Energy and Commerce Committee held a hearing entitled, Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role in Advancing U.S. Drug Development.

FDA is supporting the development of psychedelic drugs, including new treatments for serious mental health conditions.

The Reagan-Udall Foundation for the FDA and FDA are hosting a hybrid meeting on 5 August to discuss selection criteria and prioritization when considering repurposing drugs for new indications or new populations.

Manufacturing capacity already validated under 21 CFR Part 211 and existing safety dossiers could become strategic assets as the Reagan-Udall Foundation for the FDA convenes a hybrid public meeting on August 5, 2026, to shape how repurposing candidates…